esrage variants Search Results


esrage variants  (R&D Systems)
99
R&D Systems esrage variants
Comparison of AGEs, <t> sRAGE </t> isoforms, and their ratios between healthy controls (CTR) and patients with type 2 diabetes
Esrage Variants, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/esrage variants/product/R&D Systems
Average 99 stars, based on 1 article reviews
esrage variants - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
mutant green fluorescent protein mgfp  (OriGene)
92
OriGene mutant green fluorescent protein mgfp
Comparison of AGEs, <t> sRAGE </t> isoforms, and their ratios between healthy controls (CTR) and patients with type 2 diabetes
Mutant Green Fluorescent Protein Mgfp, supplied by OriGene, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mutant green fluorescent protein mgfp/product/OriGene
Average 92 stars, based on 1 article reviews
mutant green fluorescent protein mgfp - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

Image Search Results


Comparison of AGEs, sRAGE isoforms, and their ratios between healthy controls (CTR) and patients with type 2 diabetes

Journal: Cardiovascular Diabetology

Article Title: Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study

doi: 10.1186/s12933-022-01535-3

Figure Lengend Snippet: Comparison of AGEs, sRAGE isoforms, and their ratios between healthy controls (CTR) and patients with type 2 diabetes

Article Snippet: Specifically, total human sRAGE included the detection of both cRAGE and esRAGE variants (DY1145, Human RAGE DuoSet ELISA, R&D Systems Inc., MN, USA) and esRAGE concentration was evaluated by an ELISA assay with an antibody raised against the exclusive C-terminal amino acids (332–347) sequence (K1009-1, B-bridge International, CA, USA). cRAGE was determined by subtracting esRAGE from sRAGE as already described [ , , ].

Techniques: Comparison

Boxplots for the comparison of A total sRAGE, esRAGE, and cRAGE isoforms and ) AGEs/sRAGE, AGEs/esRAGE, AGEs/cRAGE, cRAGE/esRAGE ratio among healthy control subjects (CTR) and type 2 diabetes patients without (T2DM-NC) or with (T2DM-C) complications. **p < 0.01; ***p < 0.001; ****p < 0.0001 for Dunn’s post-hoc tests following Kruskal-Wallis H test

Journal: Cardiovascular Diabetology

Article Title: Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study

doi: 10.1186/s12933-022-01535-3

Figure Lengend Snippet: Boxplots for the comparison of A total sRAGE, esRAGE, and cRAGE isoforms and ) AGEs/sRAGE, AGEs/esRAGE, AGEs/cRAGE, cRAGE/esRAGE ratio among healthy control subjects (CTR) and type 2 diabetes patients without (T2DM-NC) or with (T2DM-C) complications. **p < 0.01; ***p < 0.001; ****p < 0.0001 for Dunn’s post-hoc tests following Kruskal-Wallis H test

Article Snippet: Specifically, total human sRAGE included the detection of both cRAGE and esRAGE variants (DY1145, Human RAGE DuoSet ELISA, R&D Systems Inc., MN, USA) and esRAGE concentration was evaluated by an ELISA assay with an antibody raised against the exclusive C-terminal amino acids (332–347) sequence (K1009-1, B-bridge International, CA, USA). cRAGE was determined by subtracting esRAGE from sRAGE as already described [ , , ].

Techniques: Comparison, Control

Spearman correlations of AGEs and the different isoforms of sRAGE isoforms with age in healthy controls (CTR) and patients with type 2 diabetes

Journal: Cardiovascular Diabetology

Article Title: Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study

doi: 10.1186/s12933-022-01535-3

Figure Lengend Snippet: Spearman correlations of AGEs and the different isoforms of sRAGE isoforms with age in healthy controls (CTR) and patients with type 2 diabetes

Article Snippet: Specifically, total human sRAGE included the detection of both cRAGE and esRAGE variants (DY1145, Human RAGE DuoSet ELISA, R&D Systems Inc., MN, USA) and esRAGE concentration was evaluated by an ELISA assay with an antibody raised against the exclusive C-terminal amino acids (332–347) sequence (K1009-1, B-bridge International, CA, USA). cRAGE was determined by subtracting esRAGE from sRAGE as already described [ , , ].

Techniques:

Age- and HbA1c-adjusted multiple quantile regression model for the evaluation of AGEs and sRAGE isoforms in type 2 diabetes complications

Journal: Cardiovascular Diabetology

Article Title: Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study

doi: 10.1186/s12933-022-01535-3

Figure Lengend Snippet: Age- and HbA1c-adjusted multiple quantile regression model for the evaluation of AGEs and sRAGE isoforms in type 2 diabetes complications

Article Snippet: Specifically, total human sRAGE included the detection of both cRAGE and esRAGE variants (DY1145, Human RAGE DuoSet ELISA, R&D Systems Inc., MN, USA) and esRAGE concentration was evaluated by an ELISA assay with an antibody raised against the exclusive C-terminal amino acids (332–347) sequence (K1009-1, B-bridge International, CA, USA). cRAGE was determined by subtracting esRAGE from sRAGE as already described [ , , ].

Techniques:

Univariate and multivariate Cox regression analysis for the prediction of 15-year all-cause mortality in patients with type 2 diabetes

Journal: Cardiovascular Diabetology

Article Title: Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study

doi: 10.1186/s12933-022-01535-3

Figure Lengend Snippet: Univariate and multivariate Cox regression analysis for the prediction of 15-year all-cause mortality in patients with type 2 diabetes

Article Snippet: Specifically, total human sRAGE included the detection of both cRAGE and esRAGE variants (DY1145, Human RAGE DuoSet ELISA, R&D Systems Inc., MN, USA) and esRAGE concentration was evaluated by an ELISA assay with an antibody raised against the exclusive C-terminal amino acids (332–347) sequence (K1009-1, B-bridge International, CA, USA). cRAGE was determined by subtracting esRAGE from sRAGE as already described [ , , ].

Techniques: